Abstract
Summary: Purpose: Investigate the pharmacokinetics of once‐daily (QD; 900 mg) and twice‐daily (BID; 450 mg) regimens of eslicarbazepine acetate (ESL) and BID (450 mg) regimen of oxcarbazepine (OXC) at steady state in healthy volunteers.Methods: Single‐center, open‐label, randomized, three‐way (n = 12) crossover studies in healthy volunteers.Key Findings: Mean eslicarbazepine Cmax,ss (in μm) following ESL QD (87.3) was 33.3% higher (p < 0.05) compared to ESL BID (65.5) and 82.1% higher (p < 0.05) compared to OXC BID (48.0). The mean area under the curve (AUC)ss,0–τ (in μmol h/L) following the last dose of an 8‐day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively. The ratio eslicarbazepine plasma exposure (μmol h/L) to ESL daily‐dose (μmol) was 0.381 (1156.3:3037.3), 0.368 (1117.6:3037.3), and 0.271 (968.4:3567.6) for ESL‐QD, ESL‐BID, and OXC‐BID, respectively, which translates into a 40.6% increase in the ability of ESL‐QD compared to OXC‐BID to deliver into the plasma their major active entity eslicarbazepine. The extent of plasma exposure to ESL minor metabolites: (R)‐licarbazepine and oxcarbazepine after ESL‐QD was 71.5% and 61.1% lower, respectively, than after OXC‐BID. Twenty, 24 and 38 treatment emergent adverse events were reported with ESL‐QD, ESL‐BID, and OXC‐BID, respectively.Significance: ESL‐QD resulted in 33.3% higher peak plasma concentration (Cmax,ss) of eslicarbazepine and similar extent of plasma exposure (AUCss,0–τ) when compared to ESL‐BID, which may contribute to the efficacy profile reported with once‐daily ESL. In comparison to OXC‐BID, administration of ESL‐QD resulted in 40.6% increase in the delivery of eslicarbazepine into the plasma as well as a significantly lower systemic exposure to (R)‐licarbazepine and oxcarbazepine.
Funding Information
  • BIAL - Portela & Cª, S.A.

This publication has 26 references indexed in Scilit: